NCT05589766View on ClinicalTrials.gov

N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions
Parkinson Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside supplementation up to 3000mg daily in total.

OTHER

Placebo

Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.

Trial Locations (1)

5021

Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

University of Bergen

OTHER

lead

Haukeland University Hospital

OTHER